Guess where today’s off the beaten track is from?

At major medical meetings such as ASCO21 we often hear the results of large clinical trials, many of which are dubbed “practice changing” but it’s worth remembering many of these breakthroughs first started out in the hidden corners of various poster halls, where the potential was spotted in preclinical experiments or as a signal seen in an early stage trial…

This is why we spend a lot of time at BSB looking at posters on discovery, translational and clinical data, reporting on emerging preclinical and early trial data, as well as diving deep into the science driving novel targets and biomarkers.

It turns out there are a number of novel pathways and targets at ASCO21 this year.  In this post, we’ve taken a look at several on our radar, which could be relevant if you’re interested in oncology new product development.  Where possible, we also highlight alternative perspectives from either other academic research groups or companies we have interviewed in the past for a broader perspective.

As always, we await the data to be presented at the meeting, but in a world where the challenge is figuring out the signals from the noise, this post offers a few thoughts off the well-beaten track of major clinical trials that we expect to be well covered during the meeting, and while we don’t have all the answers, we do have questions we hope the data will soon answer.

Grab a cup of coffee or your favorite beverage and join us off the beaten track in the run up to ASCO21…

To learn more about our pre ASCO meeting analysis to can get a heads up on key oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by